Cancer stem cell and epithelial–mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast

Breast Cancer Research and Treatment

Volumn 150, Issue 1, 2015, Pages 31-41

  Oon, Ming Liang ^a   Thike, Aye Aye ^b   Tan, Sie Yong ^b   Tan, Puay Hoon ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Epithelial mesenchymal transition; Metaplastic; Stem cell

Indexed keywords

34BETA E12; ALDH1A1 PROTEIN; ANTIBODY; CD24 ANTIGEN; CYTOKERATIN 14; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HERMES ANTIGEN; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR TWIST; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER STEM CELL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOEXPRESSION; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METAPLASIA; METAPLASTIC BREAST CARCINOMA; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TISSUE MICROARRAY; BREAST TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COHORT STUDIES; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PHENOTYPE; PROGNOSIS; TUMOR BURDEN;

EID: 84925489904     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3299-1     Document Type: Article

References (65)

1. Reis-Filho JS, Lakhani SR, Gobbi H, Sneige N (2012) Metaplastic carcinoma. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds) WHO classification of tumors of the breast, 4th edn. International Agency for Research on Cancer, Lyon, pp 48–52
2. Barnes PJ, Boutilier R, Chiasson D, Rayson D (2005) Metaplastic breast carcinoma: clinical–pathologic characteristics and HER2/neu expression. Breast Cancer Res Treat 91:173–178
3. Lee H, Jung SY, Ro JY et al (2012) Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol 65:441–446
4. Song Y, Liu X, Zhang G et al (2013) Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol 11:129
5. Toumi Z, Bullen C, Tang AC, Dalal N, Ellenbogen S (2011) Metaplastic breast carcinoma: a case report and systematic review of the literature. Pathol Int 61:582–588
6. Pezzi C, Patel-Parekh L, Cole K et al (2007) Characteristics and treatment of metaplastic breast cancer: analysis of 892 Cases from the National Cancer Data Base. Ann Surg Oncol 14:166–173
7. Hennessy BT, Krishnamurthy S, Giordano S et al (2005) Squamous cell carcinoma of the breast. J Clin Oncol 23:7827–7835
8. Park HS, Park S, Kim JH et al (2010) Clinicopathologic features and outcomes of metaplastic breast carcinoma: comparison with invasive ductal carcinoma of the breast. Yonsei Med J 51:864–869
9. Lim KH, Oh DY, Chie EK et al (2010) Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity. Jpn J Clin Oncol 40:112–118
10. Cooper CL, Karim RZ, Selinger C et al (2013) Molecular alterations in metaplastic breast carcinoma. J Clin Pathol 66:522–528
11. Gwin K, Buell-Gutbrod R, Tretiakova M, Montag A (2010) Epithelial-to-mesenchymal transition in metaplastic breast carcinomas with chondroid differentiation: expression of the E-cadherin repressor Snail. Appl Immunohistochem Mol Morphol 18:526–531
12. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69:4116–4124
13. Zhang Y, Toy KA, Kleer CG (2012) Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol 25:178–184
14. Lien HC, Hsiao YH, Lin YS et al (2007) Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 26:7859–7871
15. Weigelt B, Kreike B, Reis-Filho JS (2009) Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 117:273–280
16. de Beça FF, Caetano P, Gerhard R et al (2013) Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol 66:187–191
17. Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 15:178–196
18. Gerhard R, Ricardo S, Albergaria A et al (2012) Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Breast 21:354–360
19. Tsang JS, Huang Y-H, Luo M-H et al (2012) Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer. Breast Cancer Res Treat 136:407–417
20. Ginestier C, Hur MH, Charafe-Jauffret E et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567
21. Dontu G, Abdallah WM, Foley JM et al (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17:1253–1270
22. Kunju LP, Cookingham C, Toy KA et al (2011) EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol 24:786–793
23. Yang L, Ren Y, Yu X et al (2014) ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma. Mod Pathol 27:775–783
24. Deleo AB (2012) Targeting cancer stem cells with ALDH1A1-based immunotherapy. Oncoimmunology 1:385–387
25. Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33–45
26. Bourguignon LYW (2001) CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia 6:287–297
27. Jaggupilli A, Elkord E (2012) Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012:708036
28. Xu J, Lamouille S, Derynck R (2009) TGF-b-induced epithelial to mesenchymal transition. Cell Res 19:156–172
29. Thike AA, Cheok PY, Jara-Lazaro AR et al (2010) Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23:123–133
30. Wolff AC, Hammond MEH, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013
31. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111
32. Sarrio D, Rodriguez-Pinilla SM, Hardisson D et al (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989–997
33. Choi Y, Lee HJ, Jang MH et al (2013) Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer. Hum Pathol 44:2581–2589
34. Creighton C, Chang J, Rosen J (2010) Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 15:253–260
35. Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715
36. Sheridan C, Kishimoto H, Fuchs R et al (2006) CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8:R59
37. Lai H-W, Tseng L-M, Chang T-W et al (2013) The prognostic significance of metaplastic carcinoma of the breast (MCB)—A case controlled comparison study with infiltrating ductal carcinoma. The Breast 22:968–973
38. Tan EY, Thike AA, Breast Surgical Team at Outram, Tan PH (2013) ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome. Br J Cancer 109:109–113
39. Tanei T, Morimoto K, Shimazu K et al (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15:4234–4241
40. Gould Rothberg BE, Bracken MB (2006) E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res Treat 100:139–148
41. Lee HE, Kim JH, Kim YJ et al (2011) An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 104:1730–1738
42. Abraham B, Fritz P, McClellan M et al (2005) Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11:1154–1159
43. Lim S, Lee M (2002) Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep 9:915–928
44. Moody SE, Perez D, Pan TC et al (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8:197–209
45. Tse GM, Tan PH, Putti TC et al (2006) Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol 59:1079–1083
46. Kurian KM, Al-Nafussi A (2002) Sarcomatoid/metaplastic carcinoma of the breast: a clinicopathological study of 12 cases. Histopathology 40:58–64
47. Oberman HA (1987) Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am J Surg Pathol 11:918–929
48. Huvos AG, Lucas JCJ, Foote FWJ (1973) Metaplastic breast carcinoma. Rare form of mammary cancer. N Y State J Med 73:1078–1082
49. Reis-Filho JS, Milanezi F, Steele D et al (2006) Metaplastic breast carcinomas are basal-like tumours. Histopathology 49:10–21
50. Banerjee S, Reis-Filho JS, Ashley S et al (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59:729–735
51. Badve S, Dabbs DJ, Schnitt SJ et al (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24:157–167
52. O’Toole SA, Beith JM, Millar EKA et al (2013) Therapeutic targets in triple negative breast cancer. J Clin Pathol 66:530–542
53. Fulford L, Reis-Filho J, Ryder K et al (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9:R4
54. Nakshatri H, Srour EF, Badve S (2009) Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther 4:50–60
55. Jeong H, Ryu Y-j, An J, Lee Y, Kim A (2012) Epithelial–mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology 60:E87–E95
56. Karihtala P, Auvinen P, Kauppila S et al (2013) Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Breast Cancer Res Treat 138:81–90
57. Ali HR, Dawson S-J, Blows F et al (2011) Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res 13:R118
58. Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL (2010) In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol 176:2131–2138
59. Vesuna F, Lisok A, Kimble B, Raman V (2009) Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 11:1318–1328
60. Yin G, Chen R, Alvero AB et al (2010) TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 29:3545–3553
61. Battula VL, Evans KW, Hollier BG et al (2010) Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28:1435–1445
62. Nassar A, Sookhan N, Santisteban M et al (2010) Diagnostic utility of snail in metaplastic breast carcinoma. Diagn Pathol 5:76
63. Brzozowska A, Sodolski T, Duma D, Mazurkiewicz T, Mazurkiewicz M (2012) Evaluation of prognostic parameters of E-cadherin status in breast cancer treatment. Ann Agric Environ Med 19:541–546
64. Rubin MA, Mucci NR, Figurski J et al (2001) E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol 32:690–697
65. He X, Chen Z, Jia M, Zhao X (2013) Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis. PLoS One 8:e70858